Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Non-Hodgkin 1

Interventions

Specimen Handling 111Magnetic Resonance Spectroscopy 111Cyclophosphamide 109pembrolizumab 78Radiotherapy 77Nivolumab 74Cisplatin 69fludarabine 68Carboplatin 61Biopsy 53Paclitaxel 46Standard of Care 45Radiosurgery 41Gemcitabine 41Dexamethasone 40Doxorubicin 38Rituximab 37venetoclax 36Radiation 36Blood Specimen Collection 36fludarabine phosphate 35Cytarabine 35Surveys and Questionnaires 34Bevacizumab 32Capecitabine 31Radiotherapy, Intensity-Modulated 30Ipilimumab 28Etoposide 28durvalumab 27Temozolomide 27

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × efineptakin alfa × 30 days × Clear all
NCT07052305 2026-05-13

NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell Lymphoma

Washington University School of Medicine

Phase 1 Recruiting
24 enrolled
Lymphoid

Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡